Brief: Synthaverse Receives Approval For Increased ONKO BCG 100 Series
08/09/2025 07:53
Sept 8 (Reuters) - Synthaverse SA SVEP.WA: RECEIVES APPROVAL FROM AGENCY FOR REGISTRATION OF MEDICINAL PRODUCTS, MEDICAL DEVICES AND BIOCIDAL PRODUCTS FOR INCREASED ONKO BCG 100 SERIES PRODUCTION CAPACITY TO NEARLY DOUBLE FROM Q4 2025 Source text: ID:nEM4w7kTXa Further company coverage: SVEP.WA (Reporting by Gdańsk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Synthaverse SA
See all newsBrief: Synthaverse EGM To Vote On Share Capital Increase Via Series X Share Issue
Brief: Synthaverse Gets 45 Mln Zloty Loan From Polish Agency For Enterprise Development For Debt Refinancing
Brief: Synthaverse Receives Registration Certificate For Onko BCG Product In Paraguay Under Partnership With Blau
Brief: Synthaverse H1 Net Loss At 6.4 Mln Zlotys
Brief: Synthaverse Gets Poland's GIF Decision Extending Manufacturing For New Immunological Products Facility